A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study (vol 27, pg 318, 2010)

被引：3
|
作者：
Filozof, C.
Gautier, J-F
机构：
来源：
DIABETIC MEDICINE | 2013年 / 30卷 / 05期
关键词：
D O I：
10.1111/dme.12167
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：632 / 632
页数：1
相关论文
共 50 条
  • [41] Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study
    Ku, Eu Jeong
    Lee, Dong-Hwa
    Jean, Hyun Jeong
    Oh, Tae Keun
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 151 : 65 - 73
  • [42] Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study
    Wilding, J. P. H.
    Ferrannini, E.
    Fonseca, V. A.
    Wilpshaar, W.
    Dhanjal, P.
    Houzer, A.
    DIABETES OBESITY & METABOLISM, 2013, 15 (05): : 403 - 409
  • [43] Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone
    Hamann, A.
    Puig, J. Garcia
    Paul, G.
    Donaldson, J.
    Stewart, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (01) : 6 - 13
  • [44] A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study
    Kitazawa, Masaru
    Katagiri, Takashi
    Suzuki, Hiromi
    Matsunaga, Satoshi
    Yamada, Mayuko
    Ikarashi, Tomoo
    Yamamoto, Masahiko
    Furukawa, Kazuo
    Iwanaga, Midori
    Hatta, Mariko
    Fujihara, Kazuya
    Yamada, Takaho
    Tanaka, Shiro
    Sone, Hirohito
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 811 - 821
  • [45] Dapagliflozin vs glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52-week results of a double-blind, randomised, controlled trial
    Nauck, M.
    Del Prato, S.
    Rohwedder, K.
    Elze, M.
    Parikh, S.
    DIABETOLOGIA, 2010, 53 : S107 - S107
  • [46] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    Charbonnel, Bernard
    Karasik, Avraham
    Liu, Ji
    Wu, Mei
    Meininger, Gary
    DIABETES CARE, 2006, 29 (12) : 2638 - 2643
  • [47] Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial
    Wang, Weiqing
    Yang, Jinkui
    Yang, Gangyi
    Gong, Yan
    Patel, Sanjay
    Zhang, Candice
    Izumoto, Toshiyasu
    Ning, Guang
    JOURNAL OF DIABETES, 2016, 8 (02) : 229 - 237
  • [48] Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy
    Barnett, Anthony H.
    Charbonnel, Bernard
    Li, Jia
    Donovan, Mark
    Fleming, Douglas
    Iqbal, Nayyar
    CLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 707 - 717
  • [49] Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy
    Anthony H. Barnett
    Bernard Charbonnel
    Jia Li
    Mark Donovan
    Douglas Fleming
    Nayyar Iqbal
    Clinical Drug Investigation, 2013, 33 : 707 - 717
  • [50] Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy
    Barnett, A. H.
    Charbonnel, B.
    Li, J.
    Donovan, M.
    Fleming, D.
    DIABETOLOGIA, 2011, 54 : S108 - S109
12345